BIOMATRIX RECEIVES APPROVAL TO MARKET SYNVISC.RIDGEFIELD, N.J.--(BUSINESS WIRE)--March 22, 1995--Biomatrix, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BIOX) today announced that it has received approval from the Swedish Medical Products Agency (MPA MPA medroxyprogesterone acetate. ) to market Synvisc, Biomatrix' proprietary product for treating osteoarthritis of the knee, in Sweden. "We are very pleased to have received approval to market Synvisc in Sweden. This is a major milestone for Biomatrix as it is our first approval in Europe," said Endre A. Balazs, M.D., Chief Executive and Chief Scientific Officer of Biomatrix. "This is the first step toward our goal of gaining approval to market Synvisc throughout the countries of the European Union. Synvisc represents a new therapeutic modality for the treatment of osteoarthritis. Synvisc will be launched in Sweden by our distribution partner, Roche AB, in the near future." Synvisc is an innovative, elastoviscous hylan biopolymer bi·o·pol·y·mer n. A macromolecule, such as a protein or nucleic acid, that is formed in a living organism. biopolymer any protein or nucleic acid produced by a living organism. . Synvisc is injected into joints to supplement and restore the lubricating, protecting and shock absorbing properties of synovial fluid, which are compromised in osteoarthritis. The treatment, known as viscosupplementation, alleviates pain and restores joint function. Hylans are unique biopolymers derived from hyaluronan, the naturally occurring structure stabilizer stabilizer: see airplane. , lubricant and shock absorber of the human body. Hylans are highly biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. ; their effects are achieved not through pharmacological actions, but by physical means, allowing the body to resume its normal function. Clinical trials conducted by Biomatrix have shown that hylans are safe and effective in the treatment of a broad range of diseases and in other medical uses. Biomatrix, Inc., headquartered in Ridgefield, New Jersey Ridgefield is a borough in Bergen County, New Jersey, United States. As of the United States 2000 Census, the borough population was 10,830. Ridgefield was incorporated as a borough by an Act of the New Jersey Legislature on May 26, 1892, from portions of Ridgefield , is an international biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company that develops, manufactures and commercializes a series of proprietary biological polymers, called hylans, used in therapeutic medical applications and skin care. -0- Editor's note: Synvisc is a registered trademark of Biomatrix, Inc. CONTACT: Endre A. Balazs Biomatrix, Inc. 201-945-9550 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion